Skip to content
Login
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Login
Log In
Account Settings
Login
Log In
Account Settings
Login
Sign Up
Real Clinics. Real Patients. Real Oncology.
Home
/
Topics
/
Therapeutic Approaches
/
Immunotherapy
Home /
Immunotherapy
Immunotherapy
Immunotherapy
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
In My Opinion
The Limitations of Genomics-Only Liquid Biopsy: Functional Insights From Circulating Tumor Cells in Precision Oncology
Ioannis Papasotiriou
, MD, PhD, SCym
August 26, 2026
Recent Updates
KU Cancer Researchers Aim to Expand Horizons of CAR T-Cell Treatment
August 26, 2026
Recent Updates
Atezolizumab Adds No Survival Benefit to BCG for High-Risk NMIBC
August 3, 2026
Recent Updates
Immunotherapy Shows Promise in Sparing Cystectomy for High-Risk BCG-Unresponsive NMIBC
July 27, 2026
In Your Practice
Community Practices Cite Cost, Need for Prospective Data as Barriers to Biomarker Testing in Endometrial Cancer
July 17, 2026
Clinical Trials
New Trial Data Reshaping Patient Selection for Bladder Cancer Maintenance Immunotherapy
July 14, 2026
Clinical Trials
Enfortumab Vedotin Plus Pembrolizumab Combo Shows Promise for Cisplatin-Ineligible Bladder Cancer
June 26, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
June 26, 2026
Recent Updates
Ivonescimab Plus Chemotherapy Extends OS in Advanced Squamous NSCLC
June 1, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
In My Opinion
The Limitations of Genomics-Only Liquid Biopsy: Functional Insights From Circulating Tumor Cells in Precision Oncology
Ioannis Papasotiriou
, MD, PhD, SCym
August 26, 2026
Recent Updates
KU Cancer Researchers Aim to Expand Horizons of CAR T-Cell Treatment
August 26, 2026
Recent Updates
Atezolizumab Adds No Survival Benefit to BCG for High-Risk NMIBC
August 3, 2026
Recent Updates
Immunotherapy Shows Promise in Sparing Cystectomy for High-Risk BCG-Unresponsive NMIBC
July 27, 2026
In Your Practice
Community Practices Cite Cost, Need for Prospective Data as Barriers to Biomarker Testing in Endometrial Cancer
July 17, 2026
Clinical Trials
New Trial Data Reshaping Patient Selection for Bladder Cancer Maintenance Immunotherapy
July 14, 2026
Clinical Trials
Enfortumab Vedotin Plus Pembrolizumab Combo Shows Promise for Cisplatin-Ineligible Bladder Cancer
June 26, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
June 26, 2026
Recent Updates
Ivonescimab Plus Chemotherapy Extends OS in Advanced Squamous NSCLC
June 1, 2026
News & Insights
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
In My Opinion
The Limitations of Genomics-Only Liquid Biopsy: Functional Insights From Circulating Tumor Cells in Precision Oncology
Ioannis Papasotiriou
, MD, PhD, SCym
August 26, 2026
Recent Updates
KU Cancer Researchers Aim to Expand Horizons of CAR T-Cell Treatment
August 26, 2026
Recent Updates
Atezolizumab Adds No Survival Benefit to BCG for High-Risk NMIBC
August 3, 2026
Recent Updates
Immunotherapy Shows Promise in Sparing Cystectomy for High-Risk BCG-Unresponsive NMIBC
July 27, 2026
In Your Practice
Community Practices Cite Cost, Need for Prospective Data as Barriers to Biomarker Testing in Endometrial Cancer
July 17, 2026
Clinical Trials
New Trial Data Reshaping Patient Selection for Bladder Cancer Maintenance Immunotherapy
July 14, 2026
Clinical Trials
Enfortumab Vedotin Plus Pembrolizumab Combo Shows Promise for Cisplatin-Ineligible Bladder Cancer
June 26, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
June 26, 2026
Podcasts
No results were found
What are you looking for?
Search
Search
POPULAR SEARCHES
Adjuvant Therapy
Biomarker Testing
Bladder Cancer
Blood-Based Tests
